Online inquiry

IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7442MR)

This product GTTS-WQ7442MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGA2 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002203.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3673
UniProt ID P17301
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7442MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13908MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ10117MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ3940MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ15425MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-033
GTTS-WQ6684MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ15297MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ11726MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ11079MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW